节点文献

安罗替尼治疗肺癌的临床研究进展

Research progress of anlotinib in the treatment of lung cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 刘艺婧卢凯华

【Author】 LIU Yijing;LU Kaihua;Department of Medical Oncology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital;

【通讯作者】 卢凯华;

【机构】 南京医科大学第一附属医院(江苏省人民医院)肿瘤科

【摘要】 肺癌现已成为我国每年发病及死亡病例数最多的恶性肿瘤。本综述介绍了安罗替尼的作用机制,回顾了单药使用及联合用药的临床实验结果,并结合真实世界回顾性研究分析安罗替尼的疗效及使用的安全性。安罗替尼不论单药还是联合方案均有显著疗效,但受限于现有研究设计的小样本量及病例纳入标准患者的基线PS与临床现实的不完全相符,其结果存在偏差。未来我们可以着力探索安罗替尼联合治疗方案,为患者提供更理想的治疗模式选择。

【Abstract】 Lung cancer has become the most common malignant tumor in China.This artical introduces the mechanism of anlotinib, which is known as a new vascular targeting drug, and reviews the clinical experimental results of single and combined use of anlotinib.We also analyse the efficacy and safety of anlotinib used in real world.It is pointed out that both single drug and combination regimen of anlotinib have significant curative effect, but limited by the small sample size of existing research design and the fact that the baseline PS of patients in the case inclusion standard is not completely consistent with the clinical reality and the results are biased.It is suggested that we can focus on the combination regimen of anlotinib to provide patients with more ideal choice of treatment mode in the future.

【关键词】 安罗替尼肺癌单药疗效联合治疗进展
【Key words】 anlotiniblung cancersingle drugcombination therapyprogress
【基金】 国家自然科学基金(编号:81672949)
  • 【文献出处】 现代肿瘤医学 ,Journal of Modern Oncology , 编辑部邮箱 ,2021年16期
  • 【分类号】R734.2
  • 【被引频次】6
  • 【下载频次】756
节点文献中: 

本文链接的文献网络图示:

本文的引文网络